BenevolentAI Future Growth
Future criteria checks 2/6
BenevolentAI is forecast to grow earnings and revenue by 58.7% and 36.6% per annum respectively. EPS is expected to grow by 66.1% per annum. Return on equity is forecast to be -38.3% in 3 years.
Key information
58.7%
Earnings growth rate
66.1%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 36.6% |
| Future return on equity | -38.3% |
| Analyst coverage | Low |
| Last updated | 03 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 39 | -8 | 33 | 35 | 3 |
| 12/31/2025 | 29 | -19 | -39 | -35 | 4 |
| 12/31/2024 | 13 | -42 | -49 | -50 | 4 |
| 6/30/2024 | 5 | -51 | -48 | -47 | N/A |
| 3/31/2024 | 6 | -57 | -53 | -52 | N/A |
| 12/31/2023 | 7 | -63 | -58 | -57 | N/A |
| 9/30/2023 | 9 | -61 | -70 | -69 | N/A |
| 6/30/2023 | 11 | -59 | -82 | -80 | N/A |
| 3/31/2023 | 11 | -112 | -80 | -79 | N/A |
| 12/31/2022 | 11 | -164 | -78 | -77 | N/A |
| 9/30/2022 | 9 | -186 | -76 | -74 | N/A |
| 6/30/2022 | 8 | -208 | -73 | -72 | N/A |
| 3/31/2022 | 6 | -158 | -61 | -60 | N/A |
| 12/31/2021 | 5 | -108 | -50 | -49 | N/A |
| 12/31/2020 | 7 | -55 | -36 | -35 | N/A |
| 12/31/2019 | 5 | -48 | -30 | -29 | N/A |
| 12/31/2018 | 7 | -27 | -42 | -38 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2XA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2XA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2XA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2XA's revenue (36.6% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 2XA's revenue (36.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2XA is forecast to be unprofitable in 3 years.